Clinical trial · Observational
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer
NCT00890903CI-TRIAL-00007309completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule). The study focusses on concomitant antiemetic therapy and patient compliance.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Non Small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- NSCLC
- description
- Patients with advanced non-small cell lung cancer
- label
- MBC
- description
- Female patients with metastatic, Anthracycline-resistent breast cancer
Primary outcomes (1)
- measure
- Progression-free-survival
- timeFrame
- 1 year after LPI
Secondary outcomes (7)
- measure
- Time to progression
- timeFrame
- 1 year after LPI
- measure
- Adverse reactions
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years old * Male and female patients * Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC * Therapy with Navelbine capsules in any palliative treatment line * Signed patient informed consent Exclusion Criteria: * Pregnancy and nursing * All other exclusion criteria listed in SPC (summary of product characteristics) * lack of signed Patient informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.